-
2024-517727-39-00
5
2025-07-28
Covid-19 at high risk of progression to severe illness.
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2025-520705-12-00
4
2025-06-24
Colitis Ulcerative
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-519248-34-00
4
2025-06-17
Cervical Dystonia
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2024-515280-60-00
5
2025-05-29
Lupus nephritis
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-512633-32-00
4
2025-04-07
Crohn's disease
-
2024-517262-41-00
5
2025-02-28
Juvenile Psoriatic Arthritis (JPsA)
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-511775-15-00
4
2025-01-17
Immune system diseases
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-514177-21-00
4
2024-12-02
Solid tumours
-
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease